Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

(2011) K-p Kim et al.   BRITISH JOURNAL OF CANCER

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

(2010) Jaffer A. Ajani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer

(2009) Weiguo Cao et al.   ANTI-CANCER DRUGS

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group

(2009) Pasquale Comella et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Association ofCYP2A6polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer

(2009) Sun-Young Kong et al.   PHARMACOGENOMICS

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

(2008) Albert Abad et al.   ACTA ONCOLOGICA

The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer

(2008) Y Kaida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS